A Crucial Role of Interleukin-6 in the Pathogenesis of Thyrotoxicosis-related Disturbances of Bone Turnover in Mice

Abstract

Interleukin-6 (IL-6) has been shown to be involved in the pathogenesis of several bone diseases characterized by a negative balance between bone resorption and formation. The aim of the study was to estimate serum markers of bone turnover: osteoclast-derived tartrate-resistant acid phosphatase form 5a (TRACP 5b) reflecting resorption, and osteocalcin as a marker of bone formation in IL-6 knock-out mice to assess the role of IL-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone metabolism. The study was performed on forty, 14-15 weeks old, female mice: C57BL/6J (wild-type; WT) and C57BL/6J^IL6-/-Kopf (IL-6 knock-out; IL6KO). The mice were randomly divided into 4 groups with 10 mice in each one: 1. WT mice in thyrotoxicosis (WT-thx), 2. WT controls (WT-ctrl), 3. IL6KO mice with thyrotoxicosis (IL6KO-thx), and 4. IL6KO controls. Experimental model of hyperthyroidism was induced by intraperitoneal injection of levothyroxine at a dose of 1 μg/g, daily over 21 days. The serum levels of TRACP 5b and osteocalcin were determined by ELISA. Serum concentration of TRACP 5b (median and interquartile ranges) were significantly increased in both groups of mice with thyrotoxicosis: WT [28.2(18.8-41.6) U/l] and IL6KO [26.4(23.0-31.2) U/l] as compared to the respective controls. Osteocalcin serum levels in IL6KO-thx mice [111.9(103.1-175.6) ng/ml] were significantly elevated in comparison to WT-thx animals [46.1(32.5-58.9) ng/ml]. In summary, the results of the present study suggest that IL-6 plays a crucial role in thyrotoxicosis-related disturbances of bone turnover in mice, determining the imbalance between bone resorption and bone formation caused by excess of thyroid hormones predominantly by inhibition of bone formation.

IL-6 - hyperthyreosis - osteoporosis - IL-6 knock-out mice

References

• 1 Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G. Bone mineral density in hyperthyroidism.  Clin Endocrinol (Oxf). 2004;  61 466-472
• 2 Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16249 patients.  Thyroid. 2002;  12 411-419
• 3 Baldini M, Gallazzi M, Orsatti A, Fossati S, Leonardi P, Cantalamessa L. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size.  J Intern Med. 2002;  251 407-414
• 4 Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis.  J Clin Endocrinol Metab. 1999;  84 435-439
• 5 Takai S, Tokuda H, Hanai Y, Kozawa O. Phosphatidylinositol 3-kinase/Akt plays a part in Tumor Necrosis Factor α induced interleukin-6 synthesis in osteoblasts.  Horm Metab Res. 2006;  38 563-569
• 6 Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease.  Q J Med. 2002;  95 233-240
• 7 Sanchez MC, Bajo MA, Selgas R, Mate A, Sanchez-Cabezudo MJ, Lopez-Barea F, Esbrit P, Martinez ME. Cultures of human osteoblastic cells from dialysis patients: influence of bone turnover rate on in vitro selection of interleukin-6 and osteoblastic cell makers.  Am J Kidney Dis. 2001;  37 30-37
• 8 Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C- reactive protein and markers of bone resorption in postmenopausal women.  J Clin Endocrinol Metab. 2003;  88 255-259
• 9 Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.  EMBO J. 1994;  13 1189-1196
• 10 Hayashi M, Rho MC, Enomoto A, Fukami A, Kim YP, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.  Proc Natl Acad Sci USA. 2002;  12 14728-14733
• 11 O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.  Am J Physiol Endocrinol Metab. 2005;  289 E784-E793
• 12 Siddiqi A, Burrin JM, Wood DF, Monson JP. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells.  J Endocrinol. 1998;  157 453-461
• 13 Kim CH, Kim HK, Shong YK. Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: a possible mediator of thyroid hormone-induced bone loss.  J Endocrinol. 1999;  160 97-102
• 14 Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I, Tarjan G, Stern PH. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders.  J Clin Endocrinol Metab. 1997;  82 78-81
• 15 Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.  Clin Endocrinol (Oxf). 2002;  57 125-129
• 16 Fujikawa M, Kamihira K, Sato K, Okamura K, Kidota S, Lida M. Elevated bone resorption markers in a patient with hypercalcemia associated with post-partum thyrotoxicosis and hypoadrenocorticism due to pituitary failure.  J Endocrinol Invest. 2004;  27 782-787
• 17 Pantazi H, Papapetrou PD. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.  J Clin Endocrinol Metab. 2000;  85 1099-1106
• 18 Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effect of treatment.  J Clin Endocrinol Metab. 1994;  78 955-959
• 19 Murphy E, Williams GR. The thyroid and the skeleton.  Clin Endocrinol. 2004;  61 285-298
• 20 Williams GR, Bland R, Sheppard MC. Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling.  Endocrinology. 1994;  135 2375-2385
• 21 Pereira RC, Jorgetti V, Canalis E. Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts.  Am J Physiol Endocrinol Metab. 1999;  277 E496-E504
• 22 Stevens DA, Harvey CB, Scott AJ, O’Shea PJ, Barnard JC, Williams AJ, Brady G, Samarut J, Chassande O, Williams GR. Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone.  Mol Endocrinol. 2003;  17 1751-1766
• 23 Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions.  Mol Cell Endocrinol. 2003;  213 1-11
• 24 Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling.  N Engl J Med. 1995;  332 305-311
• 25 Hallen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaannen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption.  J Bone Miner Res. 2000;  15 1337-1345
• 26 Marshall K, Nash K, Haussman G, Cassady I, Hume D, Jersey J, Hamilton S. Recombinant human and mouse purple acid phosphatases: expression and characterization.  Arch Biochem Biophys. 1997;  345 230-236
• 27 O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D₃ or parathyroid hormone.  J Biol Chem. 1999;  274 19301-19308
• 28 Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T. Regulation of Matrix Metalloproteinases (MMP-2, -3, -9, and -13) by Interleukin-1 and Interleukin-6 in Mouse Calvaria: Association of MMP Induction with Bone Resorption.  Endocrinology. 1998;  139 1338-1345
• 29 Varga F, Spitzer S, Rumpler M, Klaushofer K. 1,25-Dihydroxyvitamin D3 inhibits thyroid hormone-induced osteocalcin expression in mouse osteoblast-like cells via a thyroid hormone response element.  J Mol Endocrinol. 2003;  30 49-57
• 30 Li YP, Stashenko P. Proinflammatory cytokines tumor necrosis factor-α and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter.  J Immunol. 1992;  148 788-794
• 31 Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids.  Science. 2002;  298 843-846
• 32 Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways.  J Clin Invest. 2004;  113 379-389
• 33 Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.  Ann N Y Acad Sci. 2006;  1068 225-233

Correspondence